Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Randox Launches New Ammonia Ethanol EQA Programme On RIQAS

Published: Thursday, June 26, 2014
Last Updated: Thursday, June 26, 2014
Bookmark and Share
A new Randox External Quality Assurance (EQA) programme monitoring Ammonia and Ethanol will be available on RIQAS from September 2014.

Laboratories may be asked to run ammonia blood tests by doctors when patients experience mental changes, disorientation, sleepiness, or lapse into a coma, to help investigate the cause of the change in consciousness. In patients with stable liver disease, an ammonia blood test may be requested, with other liver function tests, when a patient’s condition deteriorates suddenly. Ethanol tests are carried out to identify alcohol in the patient’s blood, as part of liver function tests.

The new RIQAS programme allows laboratories carrying out Ammonia and Ethanol testing to consolidate their EQA requirements within one programme, saving time and money. 

As the world’s largest EQA provider, with over 28000 laboratory participants in over 105 countries, RIQAS users benefit from the largest available database of results and analytical methods, thereby increasing statistical validity. RIQAS currently offers 23 comprehensive EQA programmes covering a wide range of diagnostic testing.

All RIQAS samples on the Ammonia/Ethanol programme are supplied liquid stable for ease of use, at the start of the cycle and will cover a range of clinically significant concentrations, as follows:

Ammonia : 55 - 303 umol/L Ethanol: 0.58 - 3.46 g/l

The programme offers the following features:

• Monthly reporting
• Liquid ready-to-use samples
• Comprehensive yet user friendly reports available within 3 days for quick assessment of performance
• Users can submit reports and view results online via RIQAS.net
• Participants can register up to five instruments at no extra cost.

Coming soon: An EQA programme on Erythrocyte Sedimentation Rate (ESR) will be introduced to RIQAS in 2015. ESR is a simple, non-specific screening test that indirectly measures the presence of inflammation in the body. A RIQAS pilot study is currently being conducted with results expected by the end of the year. The full programme will be distributed in line with the current RIQAS Haematology and Serology programmes from early 2015.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Randox Wins NI Hospital Trusts Business
Randox fought off global competition to win a five year contract to supply quality control products to the Northern Ireland Health & Social Care Trusts.
Monday, December 09, 2013
UK Trade and Investment Joins Hands with Randox
UK Trade and Investment organize healthcare seminars in Pakistan on “Improving Healthcare and Laboratory performance in Pakistan.”
Thursday, May 30, 2013
Newly Launched RIQAS Website Makes EQA Even Simpler for Laboratories Worldwide
www.riqas.com allows users to easily discover the many benefits offered by the world’s largest External Quality Assessment (EQA) scheme, Randox International Quality Assessment Scheme (RIQAS) and the advantages of implementing EQA in their laboratory.
Monday, March 04, 2013
You Don’t have to be a Scientist to Work in Healthcare
Randox is expanding its workforce with the recent recruitment of 42 individuals throughout October and November.
Thursday, November 15, 2012
Randox Opens New Manufacturing Facility in Bangalore, India
New Bangalore manufacturing facility to enhance product quality, ensure on time delivery and generate excellent customer satisfaction.
Friday, April 27, 2012
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!